PMID- 18534850
OWN - NLM
STAT- MEDLINE
DCOM- 20081211
LR  - 20220409
IS  - 1532-3080 (Electronic)
IS  - 0960-9776 (Linking)
VI  - 17
IP  - 5
DP  - 2008 Oct
TI  - Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast 
      cancer pre- and post-neoadjuvant chemotherapy.
PG  - 523-7
LID - 10.1016/j.breast.2008.04.002 [doi]
AB  - Neoadjuvant chemotherapy (NAC) is now a relatively standard treatment for breast 
      carcinoma. However, some tumors are known to develop resistance to 
      chemotherapies. We investigated whether the status of estrogen receptor (ER), 
      progesterone receptor (PR) and Her-2 expressions in breast cancer cases prior to 
      NAC could be changed after NAC. We used immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH) methods. No differences were found in 
      ER or Her-2 status, but a significant difference was found in PR status. Changes 
      in Her-2 status were suspected in four specimens after NAC (3+ to 1+ for 3 
      patients, and 1+ to 3+ for one patient) according to the IHC results. However, in 
      all four of these cases, FISH of the resections showed no change. When IHC 
      indicates a change in Her-2 expression after NAC, FISH is recommended.
FAU - Kasami, Masako
AU  - Kasami M
AD  - Department of Pathology, Shizuoka Cancer Center Hospital and Research Institute, 
      Sunto-Gun, Shizuoka, Japan. m.kasami@scchr.jp
FAU - Uematsu, Takayoshi
AU  - Uematsu T
FAU - Honda, Masatake
AU  - Honda M
FAU - Yabuzaki, Tsugumi
AU  - Yabuzaki T
FAU - Sanuki, Junichi
AU  - Sanuki J
FAU - Uchida, Yoshihiro
AU  - Uchida Y
FAU - Sugimura, Haruhiko
AU  - Sugimura H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080605
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/therapeutic use
MH  - Biopsy
MH  - Breast Neoplasms/*drug therapy/genetics/pathology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Japan
MH  - Middle Aged
MH  - Neoadjuvant Therapy/*adverse effects
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/genetics/*metabolism
MH  - Receptors, Progesterone/genetics/*metabolism
EDAT- 2008/06/07 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/06/07 09:00
PHST- 2007/08/30 00:00 [received]
PHST- 2008/04/04 00:00 [revised]
PHST- 2008/04/10 00:00 [accepted]
PHST- 2008/06/07 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/06/07 09:00 [entrez]
AID - S0960-9776(08)00114-8 [pii]
AID - 10.1016/j.breast.2008.04.002 [doi]
PST - ppublish
SO  - Breast. 2008 Oct;17(5):523-7. doi: 10.1016/j.breast.2008.04.002. Epub 2008 Jun 5.